Sugi Predict

Sugi Predict / Compounds / SCHEMBL4293600

SCHEMBL4293600

SCHEMBL4293600

CC(=O)Nc1ccc(/C=C/CCCCCI)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ HTT P42858 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ PPARG P37231 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ MB P02144 1/20 0.41
▸ CYP1A1 P04798 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624918 1.00 MAPT (0.46) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL4293602 1.00 MAPT (0.46) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL4291294 0.87 MAPT (0.47) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL13624924 0.87 MAPT (0.47) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL4291297 0.87 MAPT (0.47) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL4296655 0.82 PPARG (0.44) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL4296650 0.82 PPARG (0.44) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL13624925 0.78 NPC1 (0.48) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL14476694 0.77 HPGD (0.54) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL7941711 0.76 SMN1; SMN2 (0.64) MAPTMEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275664-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES PROGEN PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20080194697-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES CELLGATE, INC. 2008-08-14 — — US disclosed
US-7279502-B2 Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CELLGATE, INC. (US) 2007-10-09 — — US disclosed
US-7253207-B2 Quinones as disease therapies CELLGATE, INC. (US) 2007-08-07 — — US disclosed
US-20050233943-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CELLGATE, INC. 2005-10-20 — — US disclosed
EP-1574507-A2 Furo- and pyrano-naphthoquinones and their use in the treatment of cancer SLIL Biomedical Corporation (US) 2005-09-14 — — EP disclosed
EP-1185493-B1 QUINONES FOR TREATMENT OF DISEASES SLIL BIOMEDICAL CORP (US) 2005-07-20 — — EP disclosed
US-20050010060-A1 Novel quinones as disease therapies SLIL BIOMEDICAL CORPORATION (US) 2005-01-13 — — US disclosed
US-6809176-B2 Quinones as disease therapies SLIL BIOMEDICAL, CORPORATION 2004-10-26 — — US disclosed
US-20040006049-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases SLIL BIOMEDICAL CORPORATION (US) 2004-01-08 — — US disclosed
US-6649587-B1 Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B SLIL BIOMEDICAL CORPORATION 2003-11-18 — — US disclosed
US-20030013677-A1 QUINONES AS DISEASE THERAPIES CELLGATE, INC. 2003-01-16 — — US disclosed
US-20020183512-A1 Novel quinones as disease therapies SLIL BIOMEDICAL CORPORATION 2002-12-05 — — US disclosed
US-6482943-B1 Quinones as disease therapies SLIL BIOMEDICAL CORPORATION 2002-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010060-A1 Novel quinones as disease therapies NQO1, NDUFV2, SDHB MAPT 2177/4885MEN1 909/4885KMT2A 658/4885
US-20040006049-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CTSB, CTSL, CTSV MAPT 3032/4885MEN1 894/4885KMT2A 2180/4885
US-20030013677-A1 QUINONES AS DISEASE THERAPIES NQO1, NDUFV2, SDHB MAPT 1738/4885MEN1 856/4885KMT2A 908/4885
US-20080194697-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES CTSB, KLK3, FOLH1 MAPT 2473/4885MEN1 524/4885KMT2A 1702/4885
US-20050233943-A1 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases CTSB, CTSL, CTSV MAPT 3032/4885MEN1 894/4885KMT2A 2180/4885
US-20020183512-A1 Novel quinones as disease therapies NQO1, NDUFV2, SDHB MAPT 2177/4885MEN1 909/4885KMT2A 658/4885
US-20090275664-A1 NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES CTSB, CTSL, CTSV MAPT 3032/4885MEN1 894/4885KMT2A 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.